内科

目的探讨艾司奥美拉唑钠联合奥曲肽治疗消化性溃疡出血患者的效果。方法选取103例消化性溃疡出血患者，将其随机分为对照组（51例）和观察组（52例）。对照组给予艾司奥美拉唑钠治疗，观察组给予艾司奥美拉唑钠联合奥曲肽治疗，两组患者均治疗5 d。比较两组患者的临床疗效与临床指标，以及治疗前后的凝血功能、表皮生长因子水平、前列腺素水平；比较两组治疗期间的不良反应发生情况和随访1周期间的再出血情况。结果观察组患者的治疗总有效率（94.23%）高于对照组（72.55%）（P＜0.05）。观察组患者的消化性溃疡出血止血时间、血压稳定时间、腹痛缓解时间均短于对照组（均P＜0.05）。治疗5 d后，观察组患者的血清凝血酶原时间、活化部分凝血活酶时间均短于对照组，血清纤维蛋白原、D-二聚体水平均低于对照组，外周血血小板计数、血清表皮生长因子和前列腺素水平均高于对照组（均P＜0.05）。治疗期间，两组患者的不良反应发生率差异无统计学意义（P＞0.05）。观察组患者随访1周内的再出血发生率（4.08%）低于对照组（24.32%）（P＜0.05）。结论艾司奥美拉唑钠联合奥曲肽治疗消化性溃疡出血患者的疗效显著，可增强患者凝血功能，降低再出血风险，改善血清表皮生长因子、前列腺素水平，安全性较高。

ObjectiveTo explore the effect of esomeprazole sodium combined with octreotide in the treatment of patients with peptic ulcer bleeding. MethodsA total of 103 patients with peptic ulcer bleeding were selected and randomly divided into a control group (51 cases) and an observation group (52 cases). The control group was treated with esomeprazole sodium, while the observation group was treated with esomeprazole sodium combined with octreotide, and both groups were treated for 5 days. The clinical efficacy and clinical indicators of the two groups were compared, as well as coagulation function, epidermal growth factor level, and prostaglandin level before and after treatment, and the occurrence of adverse reactions during treatment and rebleeding during the 1-week follow-up. ResultsThe total therapeutic effective rate of the observation group (94.23%) was higher than that of the control group (72.55%) (P＜0.05). The time for hemostasis of peptic ulcer bleeding, blood pressure stabilization, and abdominal pain relief of the observation group was shorter than that of the control group (all P＜0.05). After 5 days of treatment, the serum prothrombin time and activated partial thromboplastin time of the observation group were shorter than those of the control group, and the serum fibrinogen and D-dimer levels in the observation group were lower than those in the control group, while the peripheral blood platelet count, serum epidermal growth factor and prostaglandin levels in the observation group were all higher than those in the control group (all P＜0.05). During treatment, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05). The incidence of rebleeding within the 1-week follow-up in the observation group (4.08%) was lower than that in the control group (24.32%) (P＜0.05). ConclusionEsomeprazole sodium combined with octreotide has a significant therapeutic effect on patients with peptic ulcer bleeding, which can enhance the coagulation function of patients, reduce the risk of rebleeding, and increase the levels of serum epidermal growth factor and prostaglandin, with high safety.